🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareThe GLP Lounge Community Rules — Updated January 2026 Page 3

The GLP Lounge Community Rules — Updated January 2026

Admin Mon, Feb 12, 2024 at 6:40 PM 534 replies 45,480 viewsPage 3 of 20
dave_SLC
Member
345
1,567
Aug 2024
Salt Lake City, UT
Feb 15, 2024 at 3:27 PM#11
ingrid_STO said:
Read four things before the headline number.

Saving this. It is the first explanation that did not require me to already understand it.

Last edited: Feb 15, 2024 at 7:27 PM
48 21mike_mealprep, NicoleRaleigh, james_edin and 45 others
Reply Quote Save Share Report
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Feb 15, 2024 at 10:01 PM#12

From the other side of the consultation, briefly.

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 18,000 GLP-1 users vs matched controls showed reduced all-cause mortality (HR 0.81) over 4 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
49 22InsuranceTom, WendyG_ATL, SaraMom3 and 46 others
Reply Quote Save Share Report
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Feb 16, 2024 at 4:35 AM#13
Dr.ObesityLA said:
The gap between trial results and real-world results is consistent and it is not fraud.

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

  1. Point estimate (HR/RR/OR) — center of the diamond
  2. Confidence interval width — precision of the estimate
  3. I² statistic — heterogeneity across studies
  4. Individual study weights — are results driven by one large trial?
  5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.77 (95% CI 0.71-0.82), I²=50%. This is a robust and consistent effect.

50 23RetaRick_CA, JenPlateau, SallyK_inj and 47 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Feb 16, 2024 at 11:09 AM#14
Admin said:
The GLP Lounge Community Rules — Updated January 2026 Public Square is a small room with a long memory.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

1 24Dr.PulmRoch
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Feb 16, 2024 at 5:43 PM#15

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.

2 0PurityPaulOR, MaxMetOK
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register